Amylyx Pharma DEF 14A: Executive Compensation Details
Ticker: AMLX · Form: DEF 14A · Filed: Apr 24, 2025 · CIK: 1658551
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
Related Tickers: AMLX
TL;DR
Amylyx Pharma's 2025 DEF 14A drops: exec comp, equity awards for Cohen & Klee detailed for 2022-2024.
AI Summary
Amylyx Pharmaceuticals, Inc. filed its DEF 14A on April 24, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, including equity awards granted to key personnel like Joshua Cohen and Justin Klee. It also reports changes in the fair value of outstanding equity awards for both principal executive officers (PEO) and non-PEO new executive officers (NEO) across the fiscal years 2022, 2023, and 2024.
Why It Matters
This filing provides transparency into how Amylyx Pharmaceuticals compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not present new material risks.
Key Numbers
- 20250424 — Filing Date (Date the DEF 14A was filed.)
- 20250605 — Period of Report (The period this filing pertains to.)
- 1231 — Fiscal Year End (Amylyx's fiscal year ends on December 31st.)
Key Players & Entities
- Amylyx Pharmaceuticals, Inc. (company) — Filer
- Joshua Cohen (person) — Principal Executive Officer
- Justin Klee (person) — Principal Executive Officer
- 43 Thorndike Street, Cambridge, MA 02141 (address) — Business and Mail Address
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is filed by companies to solicit proxies from shareholders for their annual or special meetings, providing detailed information about matters to be voted on, including executive compensation, director elections, and other corporate actions.
Who are the Principal Executive Officers (PEO) mentioned in relation to equity awards?
The filing references equity awards for 'PeoMember', and specifically mentions Joshua Cohen and Justin Klee in contexts related to equity awards and their fair values for fiscal years 2022-2024.
What time periods do the equity award disclosures cover?
The disclosures regarding changes in fair value of equity awards cover the fiscal years 2022, 2023, and 2024.
What is the company's Standard Industrial Classification (SIC) code?
Amylyx Pharmaceuticals, Inc. is classified under SIC code 2834, which corresponds to Pharmaceutical Preparations.
Where is Amylyx Pharmaceuticals, Inc. located?
Amylyx Pharmaceuticals, Inc. is located at 43 Thorndike Street, Cambridge, MA 02141.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 24, 2025 by Joshua Cohen regarding Amylyx Pharmaceuticals, Inc. (AMLX).